Mary Catherine Moffett: Celebrating 32 Years of Patient-Centered Advocacy with the Hemophilia Federation of America
Mary Catherine Moffett, Vice President of Policy and Advocacy at Hemophilia Federation of America, shared on LinkedIn:
”In only two short years, I’ve had the honor and privilege to be welcomed into the bleeding disorders community in my professional role at Hemophilia Federation of America, led national community organizing efforts, prepared powerful presentations about this community’s notoriety in grassroots advocacy, built a network of passionate and engaged policy advocates carrying the torch for making change, and worked with a team that is both expert in their areas of practice and has fun!
HFA celebrated 32 years as a fiercely patient centered advocacy organization in the place where we were founded that has my heart – Louisiana!
To know and honor our roots and the people who imagined this work is the strength that helps us reimagine our future.
Here are a few snapshots from the week.”

Stay updated with Hemostasis Today.
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines
-
Nov 15, 2026, 20:50Asmaa Beltagy: Efficacy and Safety of Eltrombopag in SLE-Associated Immune Thrombocytopenia
-
Nov 15, 2026, 16:29Jean-Jacques Kiladjian: 20 Years of Interferon-Alpha Research in Myeloproliferative Neoplasms
-
Nov 15, 2026, 16:21Sukanto Paul: Why Platelet Transfusion Is Generally Avoided in TTP
-
Nov 15, 2026, 16:14Ahmad G. Alzahrani: Major Bleeding and Anticoagulant Reversal
-
Nov 15, 2026, 16:05Sabine Eichinger: Is Recurrence Risk After Provoked VTE Really Low?